-
Kenya's economy faces climate change risks: World Bank
-
'Send Help' repeats as N.America box office champ
-
US astronaut to take her 3-year-old's cuddly rabbit into space
-
UK foreign office to review pay-off to Epstein-linked US envoy
-
Storm-battered Portugal votes in presidential election run-off
-
French police arrest five over crypto-linked magistrate kidnapping
-
De Beers sale drags in diamond doldrums
-
What's at stake for Indian agriculture in Trump's trade deal?
-
Pakistan's capital picks concrete over trees, angering residents
-
Neglected killer: kala-azar disease surges in Kenya
-
Chile's climate summit chief to lead plastic pollution treaty talks
-
Spain, Portugal face fresh storms, torrential rain
-
Opinions of Zuckerberg hang over social media addiction trial jury selection
-
Crypto firm accidentally sends $40 bn in bitcoin to users
-
Dow surges above 50,000 for first time as US stocks regain mojo
-
Danone expands recall of infant formula batches in Europe
-
EU nations back chemical recycling for plastic bottles
-
Why bitcoin is losing its luster after stratospheric rise
-
Stocks rebound though tech stocks still suffer
-
Digital euro delay could leave Europe vulnerable, ECB warns
-
German exports to US plunge as tariffs exact heavy cost
-
Stellantis takes massive hit for 'overestimation' of EV shift
-
'Mona's Eyes': how an obscure French art historian swept the globe
-
In Dakar fishing village, surfing entices girls back to school
-
Russian pensioners turn to soup kitchen as war economy stutters
-
As Estonia schools phase out Russian, many families struggle
-
Toyota names new CEO, hikes profit forecasts
-
Bangladesh Islamist leader seeks power in post-uprising vote
-
Japan to restart world's biggest nuclear plant
-
UK royal finances in spotlight after Andrew's downfall
-
Undercover probe finds Australian pubs short-pouring beer
-
New Zealand deputy PM defends claims colonisation good for Maori
-
Amazon shares plunge as AI costs climb
-
Deadly storm sparks floods in Spain, raises calls to postpone Portugal vote
-
Carney scraps Canada EV sales mandate, affirms auto sector's future is electric
-
Lower pollution during Covid boosted methane: study
-
Carney scraps Canada EV sales mandate
-
Record January window for transfers despite drop in spending
-
Mining giant Rio Tinto abandons Glencore merger bid
-
Davos forum opens probe into CEO Brende's Epstein links
-
ECB warns of stronger euro impact, holds rates
-
Greece aims to cut queues at ancient sites with new portal
-
ECB holds interest rates as strong euro causes jitters
-
What does Iran want from talks with the US?
-
Wind turbine maker Vestas sees record revenue in 2025
-
Bitcoin under $70,000 for first time since Trump's election
-
Germany claws back 59 mn euros from Amazon over price controls
-
Germany claws back 70 mn euros from Amazon over price controls
-
Stock markets drop amid tech concerns before rate calls
-
BBVA posts record profit after failed Sabadell takeover
Brazilian ritual root gets second life as potential anti-depressant
Long used in Indigenous Brazilian rituals, the jurema preta plant, which contains a potent psychedelic, is gaining ground as a potential treatment for depression.
At street stalls where medicinal herbs are sold, customers can buy the plant's root which contains dimethyltryptamine (DMT), a hallucinogenic substance that researchers say could be used to alleviate symptoms.
Following instructions he found on the internet, Guaracy Carvajal extracted DMT at home in 2016 from roots he bought on the street.
The 31-year-old software programmer, who had tried various treatment for chronic depression he has suffered since adolescence, said the drug makes it "feel like you've solved something in your life."
Physicist Draulio Araujo, who has conducted extensive research on the drug, said "the response is rapid. One day after treatment, (patients) already showed a significant improvement in their depression symptoms."
Yet he also warned that it "is not a magic cure" and that psychedelics "are not for everyone."
As a researcher at the Brain Institute of the Federal University of Rio Grande do Norte, Araujo and his team treated 14 people with the drug for six months.
The patients inhaled vaporized DMT, under medical supervision.
"It's common for our patients to say that something changed, that a key opened something," he said.
His patients also received psychological therapy, and some continued with conventional pharmaceutical drugs.
Neuroscientist Fernanda Palhano-Fontes, also of the Brain Institute, said "we have patients who improve significantly, others who don't improve at all."
Araujo's findings were published in the scientific journal Nature in April. In 2024, he published another study with promising results in the journal Psychedelic Medicine.
As for Carvajal, who stopped using jurema preta some time ago, he said the drug really allows a person to "start to have a lighter life."
It helped him get through a time when he was in "a state of questioning myself" about "work, day-to-day life," he said.
- Spiritual channels -
Brazil occupies a fairly prominent place in DMT research due to the substance's prominence in society, Araujo said.
While there is no ban on the cultivation or possession of jurema, which is also known as Mimosa tenuiflora, consumption of DMT is prohibited, except for religious and scientific use.
Jurema's roots are combined with other plants in a wine-like beverage that is consumed at rituals that include dancing and drums, part of Indigenous tradition in northeast Brazil where the plant grows.
"It's not hallucination," said Joyce Souza, a young woman attending a jurema ceremony in Planaltina, on the outskirts of Brasília.
"My spiritual channels become more accessible, I can communicate better with myself," Souza said.
Gathered in a house courtyard and dressed in white, the group of mostly novices waited for more seasoned practitioners to enter a trance and bring messages from ancient spirits.
Meanwhile, back in the lab, Araujo is hoping to expand his DMT research to a study of 100 patents.
"Let's say that in five years we'll have... a clear picture on when it will reach a real clinical setting," he said.
X.Cheung--CPN